PMLRARalpha and PML directly regulate Fas-mediated apoptosis in vivo
PMLRARalpha and PML directly regulate Fas-mediated apoptosis in vivo
批准号:
8245030
负责人:
FELIPE SAMANIEGO
金额:
$17.18万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2013-03-31
关键词:
Acute Promyelocytic LeukemiaApoptosisApoptoticArsenic TrioxideAttentionBindingBinding ProteinsBoxingCell LineCellsCessation of lifeChimeric ProteinsComplexDevelopmentDominant-Negative MutationGenetic TranscriptionHematologic NeoplasmsLymphocyteMalignant NeoplasmsMapsMediatingMusNuclearPatientsPreventionProteinsReceptor SignalingRegulationRetinoic Acid ReceptorRoleSignal TransductionSiteSystemTestingTherapeuticTretinoinTumor Necrosis Factor Ligand Superfamily Member 6Tumor Suppressor ProteinsXenograft procedurecancer cellcancer therapycaspase-8cell injurychemotherapyeffective therapyin vivoinhibitor/antagonistirradiationpreventpro-caspase-8public health relevancereceptorrestorationretinoic acid receptor alphatranscription factor PML
中文摘要
描述(由申请人提供):早幼粒细胞白血病(PML)/视黄酸受体(RAR) α融合蛋白(PMLRAR?)在受体信号、核转录和癌症发展的调控中处于中心地位。PMLRAR吗?通过对核转录的显性负作用,参与死亡受体信号和细胞凋亡的调控。PML是一种已知的肿瘤抑制因子,可刺激细胞凋亡,是癌症中最常见的缺陷之一(约60%)。因此,在癌症中恢复PML功能将是一种有效的治疗方法。如果直接影响PMLRAR?和PML对Fas死亡受体介导的细胞凋亡的影响,这将是了解细胞凋亡调控的一个突破,并可能为癌症治疗开辟新的可能性。我们筛选了造血癌细胞中潜在的Fas结合抑制剂,并确定了PML就是这样一种蛋白质。考虑到PML的促凋亡作用和PMLRAR的促生存作用?,我们测试了PMLRAR?阻断fas介导的细胞凋亡在初步研究中,PMLRAR?阻断Fas配体诱导的细胞凋亡。PMLRAR吗?在直接从患者身上分离的急性早幼粒细胞白血病细胞中与Fas相互作用。PMLRAR吗?-表达U937/PR9的细胞结合cFLIP并排除死亡诱导信号复合体(DISC)中的procaspase 8;因此,caspase 8的激活被阻断。还有PMLRAR的敲除?使这些细胞对fas介导的凋亡敏感。我们的假设是PMLRAR?将Fas信号转移到非凋亡终点。拟议的研究结果将对所有癌症具有重要意义,因为PMLRAR?抵消PML在细胞凋亡调节中的作用。通过展示PML和PMLRAR的直接相互作用?利用Fas,我们将揭示凋亡调控的新靶点,可用于预防和治疗许多具有PML功能缺陷的癌症。
英文摘要
DESCRIPTION (provided by applicant): The promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha fusion protein (PMLRAR?) is at the center of regulation of receptor signaling, nuclear transcription, and cancer development. PMLRAR? has been implicated in regulating death receptor signaling and apoptosis through dominant-negative effects on nuclear transcription. PML is a tumor suppressor known to stimulate apoptosis and is one of the most commonly defective (>60%) in cancers. Thus, restoration of PML function in cancer would be an effective therapy. If direct effects of PMLRAR? and PML on Fas death receptor-mediated apoptosis were to be established, this would represent a breakthrough in understanding apoptosis regulation and may open new possibilities for cancer therapy. We screened hematopoietic cancer cells for potential Fas binding inhibitors and identified PML as such a protein. Given the pro-apoptotic role of PML and pro-survival role of PMLRAR?, we tested whether PMLRAR? blocked Fas-mediated apoptosis. In preliminary studies, PMLRAR? blocked apoptosis induced by Fas ligand (FasL). PMLRAR? interacted with Fas in acute promyelocytic leukemia cells isolated directly from patients. PMLRAR? -expressing U937/PR9 cells bound cFLIP and excluded procaspase 8 in the death-induced signaling complex (DISC); thus, activation of caspase 8 was blocked. Also, knockdown of PMLRAR? in NB4 cells sensitized these cells to Fas-mediated apoptosis. Our hypothesis is that PMLRAR? diverts Fas signaling to a non-apoptosis endpoint. The results of the proposed studies will have significant implications for all cancers because PMLRAR? counters the effects of PML in apoptosis regulation. By demonstrating a direct interaction of PML and PMLRAR? with Fas, we will reveal a new target for apoptosis regulation that can be exploited for preventing and treating the many cancers that have defective PML function.
PUBLIC HEALTH RELEVANCE: The Fas system is an important cell elimination system that has several established functions, including the elimination of autoreactive lymphocytes, infected and defective cells, and cells damaged by chemotherapy and irradiation. We have identified promyelocytic leukemia protein-retinoic acid receptor as a Fas-binding protein and potential key regulator of Fas signaling. This project will characterize the binding of PML with Fas and demonstrate how Fas is regulated in acute promyelocytic leukemia cells and in mice; thus, by showing the pivotal site of regulation, we will be able to identify a therapeutic approach for the vast majority of cancers that have defective promyelocytic leukemia protein and restore apoptosis signaling.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/s12967-016-1100-9
发表时间:
2016-12-20
期刊:
Journal of translational medicine
影响因子:
7.4
作者:
[Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F]
通讯作者:
Samaniego F
Cancer Cell Overexpression of Death Receptor Modulator
-
批准号:8388622
-
项目类别:
-
资助金额:$20.62万
-
财政年份:2012
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Cancer Cell Overexpression of Death Receptor Modulator
-
批准号:8534726
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2012
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Preservation of liver function through modulation of Fas-binding proteins
-
批准号:8095442
-
项目类别:
-
资助金额:$19.75万
-
财政年份:2011
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Preservation of liver function through modulation of Fas-binding proteins
-
批准号:8333368
-
项目类别:
-
资助金额:$19.75万
-
财政年份:2011
-
负责人:FELIPE SAMANIEGO
-
依托单位:
PMLRARalpha and PML directly regulate Fas-mediated apoptosis in vivo
-
批准号:8100046
-
项目类别:
-
资助金额:$20.62万
-
财政年份:2011
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Preservation of liver function through modulation of Fas-binding proteins
-
批准号:8510636
-
项目类别:
-
资助金额:$19.06万
-
财政年份:2011
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Targeting Fas Inhibitors in Cancer Therapy
-
批准号:8111086
-
项目类别:
-
资助金额:$16.67万
-
财政年份:2010
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Targeting Fas Inhibitors in Cancer Therapy
-
批准号:7994053
-
项目类别:
-
资助金额:$20.62万
-
财政年份:2010
-
负责人:FELIPE SAMANIEGO
-
依托单位:
PKB/Akt Activation and Cell Survival with HIV-1 Tat
-
批准号:6947584
-
项目类别:
-
资助金额:$12.9万
-
财政年份:2005
-
负责人:FELIPE SAMANIEGO
-
依托单位:
PKB/Akt Activation and Cell Survival with HIV-1 Tat
-
批准号:7052884
-
项目类别:
-
资助金额:$12.6万
-
财政年份:2005
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Lymphoid Transformation with Human Herpesvirus 8 K1
-
批准号:6800706
-
项目类别:
-
资助金额:$15.77万
-
财政年份:2003
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Lymphoid Transformation with Human Herpesvirus 8 K1
-
批准号:6686881
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2003
-
负责人:FELIPE SAMANIEGO
-
依托单位:
Lymphoid Transformation with Human Herpesvirus 8 K1
-
批准号:6949737
-
项目类别:
-
资助金额:$15.77万
-
财政年份:2003
-
负责人:FELIPE SAMANIEGO
-
依托单位:
HIV 1 TATS PROMOTION OF KAPOSIS SARCOMA
-
批准号:6522488
-
项目类别:
-
资助金额:$11.99万
-
财政年份:1999
-
负责人:FELIPE SAMANIEGO
-
依托单位:
HIV 1 TATS PROMOTION OF KAPOSIS SARCOMA
-
批准号:6377058
-
项目类别:
-
资助金额:$11.99万
-
财政年份:1999
-
负责人:FELIPE SAMANIEGO
-
依托单位:
HIV 1 TATS PROMOTION OF KAPOSIS SARCOMA
-
批准号:2822647
-
项目类别:
-
资助金额:$7.02万
-
财政年份:1999
-
负责人:FELIPE SAMANIEGO
-
依托单位:
HIV 1 TATS PROMOTION OF KAPOSIS SARCOMA
-
批准号:6173994
-
项目类别:
-
资助金额:$10.91万
-
财政年份:1999
-
负责人:FELIPE SAMANIEGO
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: